Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Tovorafenib/DAY101 (Formerly TAK-580, MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors

NCT03429803 is registered in ClinicalTrials.gov with Karen D. Wright, MD as lead sponsor.

NCT NCT03429803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03429803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Tovorafenib/DAY101 (Formerly TAK-580, MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors
Lead sponsor
Karen D. Wright, MD
Phase
Phase 1
Overall status
Completed
Start date
February 27, 2018
Completion date
December 31, 2025
Enrollment
44 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

low-grade glioma